WP
PAND

Woodline Partners’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Woodline Partners’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-75,101
Closed -$861K – 291
2020
Q3 		$861K Buy
+75,101
New +$1.28M 0.03% 174

Other funds holding PAND

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Woodline Partners's PAND Position: Q4 2020 in Review

Woodline Partners sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q4 2020, closing a stake of 75,101 shares — an estimated $861K sold.

Woodline Partners first reported a position in PAND in Q3 2020 and held it in 1 quarter. The position peaked at $861K in Q3 2020. 48 funds tracked by Wall St. Rank hold PAND as of Q4 2020.

  • Woodline Partners reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Woodline Partners sold 75,101 Pandion Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $861K.
  • Woodline Partners first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Woodline Partners's Pandion Therapeutics Inc. Common Stock position peaked at $861K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q4 2020.

Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.